Benzinga•2026-04-16
Reported Earlier: 'Sun Pharma, Grünenthal Are Said to Vie for US-Listed Organon' - BloombergOGN — Organon & Co
NYSE · Pharmaceuticals · Pharmaceuticals
$8.84+23.29%Market cap1.59B
- Latest Close
- $8.84
- 30-Day Move
- +23.3%
- Market Cap
- $1.6B
- Shares Outstanding
- 260,320,000
- P/E Ratio
- 8.49
- P/B Ratio
- 2.48
Analyst consensus: Sell · 16 analysts
NYSE:OGNPharmaceuticals / PharmaceuticalsDelayed public snapshot
Organon & Co
A read-only Alphactor snapshot forOrganon & Co. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$8.84
30-Day Move
+23.3%
Market Cap
$1.6B
Shares Outstanding
260,320,000
P/E Ratio
8.49
P/B Ratio
2.48
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$8.84
+23.3%last 90 delayed daily bars
Market cap$1.6B
90D High
$9.94
90D Low
$5.69
Avg Volume
5,496,055
What stands out
Gross margin is running at 53.3%, which gives a quick read on operating quality before you open the full model.
Net margin is 3.0%, useful for comparing OGN against peers in Pharmaceuticals.
OGN is up 23.3% over the last 30 trading days shown on this page.
Latest operating income is $217M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$49.30
Rule of 40
3.3%
Dark Pool Short %
54.0%
Fundamentals snapshot
Latest Close
$8.84
30-Day Move
+23.3%
Market Cap
$1.6B
Shares Outstanding
260,320,000
P/E Ratio
8.49
P/B Ratio
2.48
ROE
24.9%
ROA
1.5%
Gross Margin
53.3%
Operating Margin
6.8%
Net Margin
3.0%
Debt / Equity
11.49
Current Ratio
1.82
Dividend Yield
1.3%
Latest Revenue
$1.5B
Financial statement snapshot
Revenue
$1.5B
Gross Profit
$741M
Operating Income
$217M
Net Income
$-205M
Gross Margin
5330.0%
Net Margin
301.0%
Current Ratio
1.82
Debt / Equity
11.49
Valuation snapshot
Fair Value
$49.30
Upside / Downside
+457.6%
Signal
Undervalued
Implied Growth
12.4%
EPV
$10.20
EV/Rev
$88.39
Growth Assumption
0.2%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$384M
Valuation spread
Current Price
$8.84
Composite Fair Value
$49.30
EPV
$10.20
EV/Rev
$88.39
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Quality snapshot
Altman Z
1.18
Distress
Piotroski
6
Moderate (4-6)
Cash Conversion
3.74x
Rule of 40
3.3%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $6.2B | $1.7B | $917M | $431M |
| 2023-12-31 | $6.3B | $1.3B | $1.0B | $538M |
| 2024-12-31 | $6.4B | $1.5B | $864M | $588M |
| 2025-12-31 | $6.2B | $1.2B | $187M | $384M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Finnhub•2026-04-16
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026Yahoo•2026-04-16
Why Organon (OGN) Is Surging as Buyout Interest Gains TractionYahoo•2026-04-15
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic DermatitisBenzinga•2026-04-15
Organon Says VTAMA Creamwas Granted Strong, Evidence-Based Recommendation By AAD In 2026 Guidelines For Management And Treatment Of AD In Pediatric Patients, Published On April 7After signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
Recent insider transactions
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-31 | Drinane Juliana Papa | M | 10,073 | $0.00 |
| 2026-03-31 | Drinane Juliana Papa | M | 6,378 | $0.00 |
| 2026-03-31 | Drinane Juliana Papa | A | 125,208 | $0.00 |
| 2026-03-31 | Drinane Juliana Papa | F | 3,451 | $5.70 |
| 2026-03-31 | Drinane Juliana Papa | M | 10,073 | $0.00 |
| 2026-03-31 | Drinane Juliana Papa | F | 2,185 | $5.70 |
| 2026-03-31 | Drinane Juliana Papa | M | 6,378 | $0.00 |
| 2026-03-31 | Falcione Aaron | M | 11,193 | $0.00 |
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 15,790,406 | 0.06% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 8,196,758 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 5,886,808 | 0.02% | 2025-12-31 |
| VANGUARD FENWAY FUNDS-Vanguard Equity Income Fund | 5,039,177 | 0.02% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Value Index Fund | 3,803,939 | 0.01% | 2025-12-31 |
| MFS SERIES TRUST XI-MFS Mid Cap Value Fund | 3,704,989 | 0.01% | 2025-12-31 |
| First TRT Exch-Trd AlphaDEX Fd.-First TRT Health Care AlphaDEX Fd. | 2,817,731 | 0.01% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 2,795,627 | 0.01% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Qube Research & Technologies
Filed 2025-05-15
--
--
BlackRock
Filed 2024-08-13
$674M
--
Vanguard Group
Filed 2025-05-09
$442M
-2.3%
Citadel Advisors
Filed 2025-05-15
$60M
--
Geode Capital Management
Filed 2025-11-12
$51M
+9.5%
Charles Schwab
Filed 2025-09-15
$49M
--
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
2.44
Consensus
SellTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
16
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.